FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      
           
This page is updated frequently with new Receptor-related patent applications. Subscribe to the Receptor RSS feed to automatically get the update: related Receptor RSS feeds. RSS updates for this page: Receptor RSS RSS


Date/App# patent app List of recent Receptor-related patents
02/26/15
20150057452
 Selective androgen receptor modulators patent thumbnailnew patent Selective androgen receptor modulators
Compounds having therapeutic potential as androgen receptor modulators, and methods of making such compounds, are provided. The compounds are structurally related to bicalutamide but bear at least one difluoromethyl or c2 to c5 perfluoroalkyl group instead of a trifluoromethyl group..
Catylix, Inc.
02/26/15
20150057360
 Methods for the treatment of tinnitus induced by cochlear excitotoxicity patent thumbnailnew patent Methods for the treatment of tinnitus induced by cochlear excitotoxicity
The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an nmda receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear.
Auris Medical Ag
02/26/15
20150057343
 Agonists of the ahr receptor pathway having sebosuppressive activity and a  identifying said agonists patent thumbnailnew patent Agonists of the ahr receptor pathway having sebosuppressive activity and a identifying said agonists
The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of ahr pathway, useful in such methods and compositions..
Thesan Pharmaceuticals, Inc.
02/26/15
20150057341
 Composition with pharmacological effect for vaporizing and method patent thumbnailnew patent Composition with pharmacological effect for vaporizing and method
A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor.
02/26/15
20150057336
 Rnai-related inhibition of tnf alpha signaling pathway for treatment of glaucoma patent thumbnailnew patent Rnai-related inhibition of tnf alpha signaling pathway for treatment of glaucoma
Rna interference is provided for inhibition of tumor necrosis factor α (tnfα) by silencing tnfα cell surface receptor tnf receptor-1 (tnfr1) mrna expression, or by silencing tnfα converting enzyme (tace/adam17) mrna expression. Silencing such tnfα targets, in particular, is useful for treating patients having a tnfα-related condition or at risk of developing a tnfα-related condition such as the ocular conditions associated with elevated intraocular pressure (top), including glaucoma and ocular hypertension..
Alcon Research, Ltd.
02/26/15
20150057331
 Novel cellular targets for hiv infection patent thumbnailnew patent Novel cellular targets for hiv infection
Methods and compositions are provided for treating hiv infection and for inhibiting hiv infection, and for identifying purinergic receptor antagonists or panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an hiv infection, or suspected of having been exposed to hiv, comprising administering to the mammalian subject an amount of (i) an antagonist of a panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) hiv fusion with a target cell, or (b) hiv replication, or (c) hiv entry into a target cell, or two or more of (a), (b) and (c)..
Albert Einstein College Of Medicine Of Yeshiva University
02/26/15
20150057328
 Proline sulfonamide derivatives as orexin receptor antagonists patent thumbnailnew patent Proline sulfonamide derivatives as orexin receptor antagonists
Wherein r1 and r2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (s)-proline sulfonamide compounds of formula (ii) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (ii), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system..
02/26/15
20150057326
 Method for synthesizing cycloalkanyl[b]indoles, cycloalkanyl[b]benzofurans, cycloalkanyl[b]benzothiophenes, compounds and methods of use patent thumbnailnew patent Method for synthesizing cycloalkanyl[b]indoles, cycloalkanyl[b]benzofurans, cycloalkanyl[b]benzothiophenes, compounds and methods of use
A method of synthesizing cycloalkanyl[b]indoles, as well as related cycloalkanyl[b]benzofurans and cycloalkanyl[b]benzothiophenes is provided. The method is a single, multicomponent reaction that combines (1) an indole, benzofuran, or benzothiopene, (2) an aldehyde, ketone, or ketal, and (3) a diene in the presence of an acid, in particular a ga(iii) or in(iii) salt.
Trustees Of Dartmouth College
02/26/15
20150057322
 Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations patent thumbnailnew patent Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a nepi.. .
Novartis Pharmaceuticals Corporation
02/26/15
20150057308
 Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives patent thumbnailnew patent Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3 -arylpropyl)imidazolidin-1-yl)-3 -arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Llc
02/26/15
20150057307
new patent

Novel modulators of sphingosine phosphate receptors


Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3.
02/26/15
20150057299
new patent

Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases


Or a pharmaceutically acceptable salt thereof, wherein r1 and r2 are as defined herein.. .
02/26/15
20150057287
new patent

Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile


Pharmaceutical compositions containing dihydroergotamine (dhe) and methods in which dhe is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with dhe are disclosed comprising: dampening the peak plasma concentration (cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms.
Map Pharmaceuticals, Inc.
02/26/15
20150057268
new patent

Composition and neuropeptide s receptor (npsr) antagonists


Neuropeptide s receptor antagonists are provided that bind in functional assays to neuropeptide s receptors; methods are provided for use of these antagonists in treatment of conditions or disease states that are ameliorated by blocking of the neuropeptide s receptor, including substance abuse and substance abuse relapse; and for use of neuropeptide s receptor antagonists in the manufacture of therapeutics and pro-drugs for therapeutics useful in disease states and conditions sensitive to binding of the neuropeptide s receptor.. .
Research Triangle Institute
02/26/15
20150057261
new patent

Azetidine derivatives as sphingosine-1 phosphate receptors modulators


The present invention relates to azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
Allergan, Inc.
02/26/15
20150057258
new patent

4-pregenen-11beta-17-21-triol-3,20-dione derivatives


The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation..
Allergan, Inc.
02/26/15
20150057256
new patent

Novel polymorphic crystal forms of 5-(2--1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisytlate as agonist of the beta2 adrenergic receptor


The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms..
Almirall, S.a.
02/26/15
20150057255
new patent

Use of nk-1 receptor antagonists in pruritus


The invention relates to methods for treating pruritus with nk-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising nk-1 receptor antagonists such as serlopitant.
Tigercat Pharma, Inc.
02/26/15
20150057253
new patent

Alkyl derivatives as sphingosine-1 phosphate receptors modulators


The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
Allergan, Inc.
02/26/15
20150057248
new patent

Bivalent ampa receptor positive allosteric modulators


Embodiments of the invention are directed to compounds that are positive allosteric modulators of ampa receptors.. .
The Board Of Regents Of The University Of Texas System
02/26/15
20150057227
new patent

Compositions, devices and methods of use thereof for the treatment of cancers


The use of glp-1 receptor agonists, such as glucagon-like peptide-1 (glp-1) or exenatide, for the treatment of cancer is described. The glp-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the glp-1 receptor agonist for at least one month.
Intarcia Therapeutics, Inc.
02/26/15
20150057173
new patent

Methods for determining the tropism and receptor usage of a virus, in particular hiv, in body samples taken from the circulation


The present invention relates to microarrays, sets of primers and methods for determining the co-receptor usage of a virus, in particular whether hiv uses cxcr4 or ccr5 as co-receptor. The methods and compositions of the invention are based on microrna analysis.
Universite Montpellier 2 Sciences Et Techniques
02/26/15
20150057166
new patent

Method for analyzing the three dimensional structure of a gpcr


Certain embodiments provide a method for crystallizing a gpcr. The method may employ a fusion protein comprising, from n-terminus to c-terminus: a) a first portion of a family c g-protein coupled receptor (gpcr), wherein the first portion comprises the tm1, tm2 and tm3, regions of the gpcr; b) a stable, folded protein insertion; and c) a second portion of the gpcr, wherein the second portion comprises the tm4, tm5 tm6 and tm7 regions of the gpcr..
Confometrx, Inc.
02/26/15
20150056621
new patent

Primers, methods and kits for detecting killer-cell immunoglobulin-like receptor alleles


Embodiments of the present invention describe primer pairs, methods and kits for identifying and/or detecting killer-cell immunoglobulin-like receptor (kir) alleles. The present primer sets include one or more primer pairs that can produce amplicons specific for an individual kir allele and that are less than 1000 bp in size.
Life Technologies Corporation
02/26/15
20150056238
new patent

Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof


This present invention provides c-tab.g5 and c-tab.g5.1 isolated polypeptides comprising the receptor binding domains of c. Difficile toxin a and toxin b as set forth in the amino acid sequences of seq id no: 2 and seq id no: 4.
Valneva Austria Gmbh
02/26/15
20150056226
new patent

Immunotherapeutic agent


The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an il-2 gene or a water-soluble tgf-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy..
Catholic University Industry Academic Cooperation Foundation
02/26/15
20150056224
new patent

Compositions and methods for activating stimulator of interferon gene-dependent signalling


The present invention provides highly active cyclic-di-nucleotide (cdn) immune stimulators that activate dcs via a recently discovered cytoplasmic receptor known as sting (stimulator of interferon genes). In particular, the cdns of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce sting-dependent type i interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2′,5′,2′,5′ and 2′,5′,3′,5′ cdns, and preferably rp,rp stereosiomers thereof..
The Regents Of The University Of California
02/26/15
20150056222
new patent

Anti-prlr antibodies and uses thereof


The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056221
new patent

Anti-prlr antibodies and uses thereof


The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.
02/26/15
20150056219
new patent

Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors


Methods and compositions are disclosed to target tumor cells with embodiments of the light proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human light protein.
The University Of Chicago
02/26/15
20150056217
new patent

Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4 associated disorders


The present invention relates to the use of a tlr9 agonist and/or a tlr4 antagonist and/or a nod2 agonist for treatment or prevention of disorders involving tlr4 activation, such as systemic sepsis and necrotizing enterocolitis.. .
University Of Pittsburgh - Of The Commonwealth System Of Highter Education
02/26/15
20150056204
new patent

Dr5 receptor agonist combinations


The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of nk cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human dr5, or a cooperative combination of an anti-dr5 antibody and trail.
Amgen Inc.
02/26/15
20150056199
new patent

Tgf-beta receptor type ii variants and uses thereof


In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of tβrii polypeptide useful to selectively antagonize a tβrii ligand. The disclosure further provides compositions and methods for use in treating or preventing tgfβ associated disorders..
Acceleron Pharma, Inc.
02/26/15
20150056185
new patent

Immunoglobulin constant region fc receptor binding agents


Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
University Of Maryland, Baltimore
02/19/15
20150051502

Breath analyzer, system, and computer program for authenticating, preserving, and presenting breath analysis data


A breath analyzer, a system, and a computer program for administering a breath analysis to a donor and recording a breath analysis result. Embodiments of the invention authenticate that the breath analysis was performed correctly, preserves the breath analysis results by communicating with other devices, and presents the breath analysis results by superimposing them on recorded video data.
Digital Ally, Inc.
02/19/15
20150051399

Processes for preparing tubulysin derivatives and conjugates thereof


The invention described herein pertains to processes for preparing tubulysin derivatives, conjugates of tubulysins, and intermediates therefore. In one illustrative embodiment of the invention, processes for derivatives or analogs of natural tubulysins including compounds of formula (t).
Endocyte, Inc.
02/19/15
20150051299

Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists


Disclosed are compositions comprising beta-caryophyllene (bcp) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using bcp. Disclosed are also compositions comprising cb2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using cb2 receptor agonists..
Napromed Biopharmaceuticals Gmbh
02/19/15
20150051291

N,n'-di-1 naphthylguanidine hcl (nagh) and n,n'-di-p-nitrophenylguanidine hcl (nad) treatment for stroke at delayed timepoints


A composition and method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after mcao, systemic administration of several novel sigma agonists including: bromo-dtg; chloro-dtg; n,n′-di-1-naphthylguanidine hydrochloride (nagh); n,n′-di-p-nitrophenylguanidine hcl (nad) or vehicle were injected subcutaneously daily for 3 days.
University Of South Florida
02/19/15
20150051285

Alkylamido compounds and uses thereof


Disclosed herein are compounds that may be specific to ppar and/or egf receptors, and methods of making and using same.. .
Nogra Pharma Limited
02/19/15
20150051271

Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist


The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of
02/19/15
20150051266

Chimeric antigen receptors targeting b-cell maturation antigen


The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (car) directed against b-cell maturation antigen (bcma). The invention also provides host cells, such as t-cells or natural killer (nk) cells, expressing the car and methods for destroying multiple myeloma cells..
The Usa, As Represented By The Secretary, Department Of Health And Human Serivces
02/19/15
20150051262

Nmda receptor modulators and uses thereof


Disclosed are compounds having enhanced potency in the modulation of nmda receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
Northwestern University
02/19/15
20150051259

Pro-inflammatory mediators in diagnosis and treatment of pulmonary disease


Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of copd that can be used predict the presence of copd and/or subtypes of copd in human patients.
National Jewish Health
02/19/15
20150051247

Compounds and methods for treating cancer by inhibiting the urokinase receptor


Compounds and methods for treating or preventing cancer associated with binding to the urokinase receptor are provided. Biological processes affected by the compounds include cell migration, cell growth, cell adhesion, angiogenesis, cancer cell invasion, apoptosis, tumor formation, tumor progression, metastasis, degradation of the extracellular matrix, pericellular proteolysis, activation of plasminogen, changes in the levels of an extracellular protease, and changes in the levels of a vegf receptor..
02/19/15
20150051243

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists


Wherein r2, r7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
02/19/15
20150051239

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
Abbvie Bahamas Limited
02/19/15
20150051238

Pyrazole aminopyrimidine derivatives as lrrk2 modulators


Pyrazole compounds that are modulators of lrrk2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with lrrk2 receptor, such as parkinson's disease.. .
Genentech, Inc.
02/19/15
20150051234

Therapy for complications of diabetes


A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelia a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg
02/19/15
20150051214

Liver x receptor modulators


Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver x receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier.
Vitae Pharmaceuticals, Inc.
02/19/15
20150051201

Bicyclic pyrazole lrrk2 small molecule inhibitors


Wherein x, r1, r2, r3 and a are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with lrrk2 receptor, such as parkinson's disease..
02/19/15
20150051197

Heterocyclic compound and use thereof


Wherein each symbol is as defined in the description, or a salt thereof has an ampa receptor function enhancing action, and is useful as a prophylactic or therapeutic drug for depression, schizophrenia, alzheimer's disease or attention deficit hyperactivity disorder (adhd) and the like.. .
02/19/15
20150051192

Blocking of cue-induced drug reinstatement


A method of preventing drug use relapse by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement.
Albany Medical College
02/19/15
20150051186

Aryl azetidine derivatives as sphingosine-1 phosphate receptors modulators


The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. .
Allergan, Inc.
02/19/15
20150051183

Conformationally constrained, fully synthetic macrocyclic compounds


The conformationally restricted, spatially defined macrocyclic ring system of formula (i) is constituted by three distinct molecular parts: template a, conformation modulator b and bridge c. Macrocycles described by this ring system i are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase.
Polyphor Ag
02/19/15
20150051178

Estriol therapy for autoimmune and neurodegenerative diseases and disorders


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California
02/19/15
20150051176

Aryl derivatives as sphingosine-1 phosphate receptors modulators


The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. .
Allergan, Inc.
02/19/15
20150051166

Methods of treating neurological diseases


The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of contacting the hippocampus in said subject with a compound effective to restore excitatory/inhibitor balance thereby controlling the neural circuit hyperexcitability. Further provided is a method of treating a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comprising the step of administering an amount of an adenosine a1 receptor agonist pharmacologically effective to block epileptogenetic activities without blocking excitatory synaptic transmission..
02/19/15
20150051161

Methods for the detection of advanced glycation endproducts and markers for disease


The present invention provides compositions and methods for detecting carboxymethyl-lysine (cml) and circulating receptor for advanced glycation end (rage) products, and methods for correlating cml and rage levels with age-related disease. In particular, serum cml and/or circulating receptor for advanced glycation end (rage) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes..
The Johns Hopkins University
02/19/15
20150051136

Human soluble receptor for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage


The present disclosure provides a method for recombinant production of human srage in mammalian cells, as well as a human srage having a mammalian post-translational modification and compositions thereof. The present disclosure also provides a method of treating a vascular disease, injury, or inflammation in a mammal by administering to a mammal with a vascular disease, injury, or inflammation a composition comprising human srage having a mammalian post-translational modification, thereby treating the vascular disease, injury, or inflammation in the mammal..
The United States Of America,as Represented By The Secretary, Department Of Health And Human Service
02/19/15
20150051091

Methods of selecting epidermal growth factor receptor (egfr) binding agents


The present application relates to methods of selecting egfr binding agents. In certain embodiments, such egfr binding agents bind to at least a portion of a panitumumab epitope on an egfr.
02/19/15
20150050723

Optoelectronic detection system


The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals.
Massachusetts Institute Of Technology
02/19/15
20150050670

Combinatorial gamma 9 delta 2 t cell receptor chain exchange


The current invention provides methods to identify γ9δ2t-cell receptors (γ9δ2tcr) that mediate anti-tumour responses. Surprisingly, it was now found that the cdr3 regions of the γ9-t-cell receptor chain and the δ2-t-cell receptor chain (δ2tcr chain) are of importance.
Umc Utrecht Holding B.v.
02/19/15
20150050589

Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, and image forming apparatus


The present invention relates to an electrophotographic photoreceptor comprising a conductive support and at least a photosensitive layer provided thereon, wherein the electrophotographic photoreceptor comprises an outermost layer which contains a specific charge transport substance and a specific compound.. .
Mitsubishi Chemical Corporation
02/19/15
20150050346

Compositions and methods for treating insulin resistance and diabetes mellitus


Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents.
Revalesio Corporation
02/19/15
20150050343

Methods of wound care and treatment


Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.
Revalesio Corporation
02/19/15
20150050294

Methods for diagnosing and treating neuroendocrine cancer


The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of n-methyl d-asparate-associated (nmda) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed..
Trustees Of Dartmouth College
02/19/15
20150050289

Muscle specific receptor kinase and modulation thereof


Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (musk) and methods and uses thereof to modulate musk activity are encompassed herein. Also encompassed are screening assays to identify modulators of musk activity.
New York University
02/19/15
20150050280

Soluble human m-csf receptor and uses thereof


Methods of using m-csf antibodies to treat macrophage-associated diseases including atherosclerosis and hiv are provided.. .
Xoma Technology Ltd.
02/19/15
20150050279

B-cell receptor complex binding proteins containing t-cell epitopes


The present invention relates to a polypeptide comprising a) a binding peptide binding to at least one protein selected from the group consisting of cd22, cd19, cd20, and cd21, and b) an immunogenic peptide comprising at least one t-cell epitope for use in vaccination of a subject against b-cell hyperproliferation or for use in the modulation of the immune response in a subject. The present invention further relates to a polynucleotide and a vector encoding said polypeptide and a host cell comprising the same.
Deutsches Krebsforschungszentrum
02/19/15
20150050278

Soluble engineered monomeric fc


Fc domains and ch3 domains are disclosed that bind the neonatal fc (fcrn) receptor and are at least 99% monomeric. Monomeric fc domain molecules and ch3 domain molecules are disclosed herein that include a monomeric fc domain or a monomeric ch3 domain and an effector molecule.
The United States Of America, As Represented By The Secretary, Dep. Of Health And Human Sevices
02/19/15
20150050270

Antibodies to bradykinin b1 receptor ligands


The invention provides antibodies that specifically bind to kallidin or des-arg10-kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-kallidin or des-arg10-kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof.
Sanofi
02/19/15
20150050269

Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities


The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human fcrn under an acidic ph range condition; (ii) of binding under a neutral ph range condition to human fc receptor stronger than native human igg, and (iii) that its antigen-binding activity alters according to the ion concentration.. .
Chugai Seiyaku Kabushiki Kaisha
02/19/15
20150050212

Cholecystokinin b receptor targeting for imaging and therapy


Conjugates are described herein where cck2r targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer..
Purdue Research Foundation


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.3639

3549

1 - 1 - 79